A panel of antibiotic experts appointed by the FDA will meet Feb. 27 to review Theravance's injectable antibiotic telavancin for the treatment of skin infections caused by "superbug" bacteria. The next day, the panel will consider the approval of Johnson & Johnson's antibiotic for diabetes-related foot infections, the agency announced.

Full Story:
Forbes, Forbes

Related Summaries